MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
LOS ANGELES, Aug. 24, 2012 /PRNewswire/ — MedQIA has developed a software toolkit of image analysis routines that forms the basis of an Imaging Biomarker Information System (IBIS). It employs a model-based engine to segment the lung, lobes, segments, and airways. IBIS provides computer-assisted diagnosis of the lung from CT for early diagnosis, treatment planning and outcome assessment.
MedQIA applies cutting-edge biomarkers based on lung texture analysis; these include assessment of honeycombing, ground-glass and lung fibrosis scoring, applied in assessment of scleroderma lung disease and interstitial pulmonary fibrosis (IPF).´
The QIA approach complements conventional pulmonary function tests (PFTs) because it is minimally-invasive and able to perform both global and regional assessment of the lung, thus providing greater sensitivity. IBIS allows a variety of validated quantitative measures to be derived from any segmented lung region or subregion (e.g. lung lobe, segment, anterior, middle or posterior zone, central or peripheral zone and combination zones such as posterior peripheral, middle peripheral, etc.).
Lung imaging biomarkers include: Volumetry, Attenuation Analysis, Texture Classification, Fibrosis Scoring, Dynamic Imaging, Airway Morphometry, and Fissure Integrity Scoring.
MedQIA is a full service global Imaging CRO that specializes in Computer Vision systems for automated image analysis and measurement. Computer-calculated imaging biomarkers are more accurate, sensitive, and reproducible than manual human measurements. This results in shorter trials with fewer subjects and enables adaptive study designs. What sets us apart is our ability to develop and validate novel imaging biomarkers for use in global, regulated clinical trials.
MedQIA provides a full range of core laboratory services and handles all aspects of your clinical trial from planning to completion.
For more information please visit our website at www.medqia.com
Contact Information: Juliette Bridges, M.S., MBA – Business Development Manager: email@example.com 1-888-963-3742
´Kim HJ, Brown MS, Elashoff R, Li G, Gjertson DW, Lynch DA, Strollo DC, Kleerup E, Chong D, Shah SK, Ahmad S, Abtin F. Tashkin DP, Goldin JG. Quantitative texture-bases assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. European Radiology 2011 DOI 10.1007/s00330-011-2223-2.